Lexicon Genetics Newswire

Lexicon Genetics Newswire

Comprehensive Real-Time News Feed for Lexicon Genetics.

Results 1 - 20 of 203 in Lexicon Genetics

  1. Lexicon Pharmaceuticals, Inc. (LXRX) Given "Outperform" Rating at WedbushRead the original story w/Photo

    Yesterday | AmericanBankingNews.com

    's stock had its "outperform" rating reaffirmed by equities research analysts at Wedbush in a report released on Tuesday. They currently have a $33.00 target price on the biopharmaceutical company's stock.

    Comment?

  2. Auto DraftRead the original story w/Photo

    Yesterday | AmericanBankingNews.com

    's stock had its "outperform" rating reissued by equities researchers at Wedbush in a research note issued to investors on Tuesday. They currently have a $33.00 target price on the biopharmaceutical company's stock.

    Comment?

  3. Biotech Movers And Shakers: Lexicon Pharmaceuticals, Inc.Read the original story w/Photo

    Tuesday | Insider Monkey

    Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages. We only allow registered users to use ad blockers.

    Comment?

  4. Lexicon Pharma Reports Top-Line Results From Phase 2 Clinical Trial Conducted In Collaboration WithRead the original story

    Monday | BioSpace

    The purpose of this Phase 2 clinical trial, which randomized a total of 87 patients, was to assess the effects of a once-daily 400 mg dose of sotagliflozin compared to a placebo control in insulin-treated young adults with type 1 diabetes, aged 18-30 years, and particularly high baseline A1C levels of greater than or equal to 9.0%, representative of an at-risk population in which glycemic control and adherence to therapy are substantial challenges. The study promoted adherence and encouraged insulin adjustment as needed to achieve glucose control targets.

    Comment?

  5. Lexicon's sotagliflozin flunks mid-stage study; shares off 9% after hoursRead the original story w/Photo

    Monday | Seeking Alpha

    Lexicon Pharmaceuticals slumps 9% after hours on robust volume in response to its announcement that a Phase 2 clinical trial assessing sotagliflozin in type 1 diabetics failed to achieve the primary endpoint. The study randomized 87 young adults with insulin-treated type 1 diabetes who had high baseline A1C levels to receive once-daily sotagliflozin 400 mg or placebo.

    Comment?

  6. BRIEF-Lexicon reports top-line results from phase 2 clinical trial...Read the original story w/Photo

    Monday Dec 5 | Reuters

    The currency hit its strongest level in mor BRIEF-News Corp says Elaine Chao notified co she will resign from board if and when confirmed Secretary of Transportation * News Corp - on December 2, 2016, Elaine Chao notified co that she will resign from board effective if and when she is confirmed as Secretary of Transportation Source text for Eikon: Further company coverage:

    Comment?

  7. Lexicon Reports Top-Line Results From Phase 2 Clinical Trial Conducted In Collaboration With JDRFRead the original story w/Photo

    Dec 31, 2015 | PR Newswire

    The purpose of this Phase 2 clinical trial, which randomized a total of 87 patients, was to assess the effects of a once-daily 400 mg dose of sotagliflozin compared to a placebo control in insulin-treated young adults with type 1 diabetes, aged 18-30 years, and particularly high baseline A1C levels of greater than or equal to 9.0%, representative of an at-risk population in which glycemic control and adherence to therapy are substantial challenges. The study promoted adherence and encouraged insulin adjustment as needed to achieve glucose control targets.

    Comment?

  8. Lexicon Pharmaceuticals Inc. (LXRX) Given Consensus Rating of "Hold" by AnalystsRead the original story w/Photo

    Sunday Dec 4 | IntersportsWire

    Lexicon Pharmaceuticals Inc. has earned an average recommendation of "Hold" from the nine ratings firms that are currently covering the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company.

    Comment?

  9. Lexicon Pharmaceuticals, Inc. (LXRX): Are Hedge Funds Right About This Stock?Read the original story w/Photo

    Friday Dec 2 | Insider Monkey

    Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages. We only allow registered users to use ad blockers.

    Comment?

  10. Lexicon Pharmaceuticals Inc. (LXRX) Given Average Recommendation of "Hold" by BrokeragesRead the original story w/Photo

    Tuesday Nov 29 | AmericanBankingNews.com

    Lexicon Pharmaceuticals Inc. has earned an average recommendation of "Hold" from the nine research firms that are presently covering the company. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and five have issued a buy recommendation on the company.

    Comment?

  11. Lexicon Pharmaceuticals' (LXRX) "Buy" Rating Reiterated at HC WainwrightRead the original story w/Photo

    Sunday Nov 27 | AmericanBankingNews.com

    LXRX has been the subject of a number of other research reports. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a "hold" rating to a "buy" rating and set a $20.00 target price for the company in a report on Wednesday, October 5th.

    Comment?

  12. Lexicon Announces The Establishment Of The Commercial Leadership Team For Telotristat EthylRead the original story w/Photo

    Monday Nov 21 | Freshnews

    Lexicon Pharmaceuticals, Inc. , today announced the appointments of Alexander Santini as chief commercial officer, Kiernan Seth, Ph.D. as vice president of marketing, and Gary Branch as vice president of sales. Mr. Santini will have responsibility for all commercial activities in the United States for telotristat ethyl, an investigational oral drug for the treatment of carcinoid syndrome, with Dr. Seth and Mr. Branch reporting directly to him.

    Comment?

  13. Mid-Morning Market Update: Markets Rise; Donald Trump Wins 2016 Presidential ElectionRead the original story

    Wednesday Nov 9 | Benzinga

    Following the market opening Wednesday, the Dow traded up 0.41 percent to 18,407.26 while the NASDAQ climbed 0.19 percent to 5,203.32. The S&P also rose, gaining 0.06 percent to 2,140.85.

    Comment?

  14. Investment Analysts' Weekly Ratings Updates for Intercept PharmaceuticalsRead the original story w/Photo

    Tuesday Nov 8 | AmericanBankingNews.com

    They now have a $332.00 price target on the stock. 11/3/2016 - Intercept Pharmaceuticals had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $350.00 price target on the stock.

    Comment?

  15. Lexicon Pharmaceuticals Acquires Exclusive Rights To Development...Read the original story w/Photo

    Monday Nov 7 | Freshnews

    Lexicon Pharmaceuticals, Inc. announced today that it has obtained exclusive research, development and commercialization rights to LX9211 , a development candidate for neuropathic pain that was jointly developed by Lexicon and Bristol-Myers Squibb Company as part of their neuroscience drug discovery alliance. Additional small molecule compounds acting through the same target as LX9211 are also included in the exclusive arrangement.

    Comment?

  16. Lexicon Gains Rights to Pain Drug in BMS AllianceRead the original story w/Photo

    Monday Nov 7 | Contract Pharma Breaking News

    Lexicon Pharmaceuticals, Inc. has obtained exclusive research, development and commercialization rights to LX9211 , a drug candidate for neuropathic pain that was jointly developed by Lexicon and Bristol-Myers Squibb as part of their neuroscience drug discovery alliance. Additional small molecule compounds acting through the same target as LX9211 are also included in the exclusive agreement.

    Comment?

  17. Recent Research Analysts' Ratings Updates for Lexicon PharmaceuticalsRead the original story w/Photo

    Nov 3, 2016 | AmericanBankingNews.com

    ... by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. According to Zacks, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. ...

    Comment?

  18. Lexicon Pharmaceuticals Inc. (LXRX) Earns "Buy" Rating from HC WainwrightRead the original story w/Photo

    Nov 2, 2016 | Daily Political

    Other equities analysts also recently issued research reports about the stock. Wedbush reaffirmed a "buy" rating and set a $33.00 price target on shares of Lexicon Pharmaceuticals in a research note on Thursday, October 27th.

    Comment?

  19. Equities Research Analysts' Updated EPS Estimates for November, ...Read the original story w/Photo

    Nov 2, 2016 | AmericanBankingNews.com

    The firm currently has a GBX 240 target price on the stock. had its equal weight rating reaffirmed by analysts at Barclays PLC.

    Comment?

  20. Lexicon Pharmaceuticals Inc. (LXRX) Rating Reiterated by WedbushRead the original story w/Photo

    Nov 2, 2016 | Daily Political

    The firm currently has a $33.00 price objective on the biopharmaceutical company's stock. Several other research analysts have also commented on LXRX.

    Comment?